Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Diluted Average): 2022-2024

Historic Shares Outstanding (Diluted Average) for Silence Therapeutics (SLN) over the last 3 years, with Dec 2024 value amounting to $138.8 million.

  • Silence Therapeutics' Shares Outstanding (Diluted Average) fell 22.76% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year decrease of 22.76%. This contributed to the annual value of $138.8 million for FY2024, which is 0.25% up from last year.
  • As of FY2024, Silence Therapeutics' Shares Outstanding (Diluted Average) stood at $138.8 million, which was up 0.25% from $138.4 million recorded in FY2023.
  • Silence Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $138.8 million for FY2024, and its period low was $119.5 million during FY2022.
  • In the last 3 years, Silence Therapeutics' Shares Outstanding (Diluted Average) had a median value of $138.4 million in 2023 and averaged $132.2 million.
  • Data for Silence Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 15.79% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Silence Therapeutics' Shares Outstanding (Diluted Average) stood at $119.5 million in 2022, then increased by 15.79% to $138.4 million in 2023, then grew by 0.25% to $138.8 million in 2024.